Staining of MUC1 in ovarian cancer tissues with pankomab-GEX™ detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8

Histology and Histopathology

Volumn 28, Issue 2, 2013, Pages 239-244

  Dian, Darius ^a   Lenhard, Miriam ^a   Mayr, Doris ^a   Heublein, Sabine ^a   Karsten, Uwe ^b   Goletz, Steffen ^b   Kuhn, Christina ^a   Wiest, Irmi ^a   Friese, Klaus ^a   Weissenbacher, Tobias ^a   Jeschke, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b GLYCOTOPE GMBH   (Germany)

Author keywords

Immunohistochemistry; MUC1; Ovarian cancer; PankoMab GEX ; Prognosis; Tumour specificity

Indexed keywords

DIAGNOSTIC AGENT; EPITOPE; MONOCLONAL ANTIBODY; MUCIN 1; PANKOMAB GEX; PANKOMAB-GEX; PEMTUMOMAB; TUMOR MARKER;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; ARTICLE; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; FEMALE; HISTOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; OVARY; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STAINING;

ADENOCARCINOMA, CLEAR CELL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; CARCINOMA, ENDOMETRIOID; EPITOPES; FEMALE; HISTOLOGICAL TECHNIQUES; HUMANS; MUCIN-1; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; OVARY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 84873844780     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bhattacharya-Chatterjee M., Mrozek E., Mukerjee S., Ceriani R.L., Kohler H. and Foon K.A. (1994). Anti-idiotype antibodies as potential therapeutic agents for human breast cancer. Adv. Exp. Med. Biol. 353, 139-148.
2. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., Carpenter M. and LoBuglio A.F. (2003). Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9, 3731-3741.
3. Burchell J., Durbin H. and Taylor-Papadimitriou J. (1983). Complexity ofexpression of antigenic determinants, recognized by monoclonalantibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J. Immunol. 131, 508-513.
4. Collignon J., Gennigens C., Rorive A., Coucke P., Lifrange E., Maweja S., Fillet G. and Jerusalem G (2009). Monoclonal antibodies and breast cancer. Current therapeutic progress. Rev. Med. Liege 64, 279-283. (In Belgium)
5. Danielczyk A., Stahn R., Faulstich D., Loffler A., Marten A., Karsten U. and Goletz S. (2006). PankoMab: a potent new generation antitumour MUC1 antibody. Cancer Immunol. Immunother. 55, 1337-1347.
6. Dian D., Janni W., Kuhn C., Mayr D., Karsten U., Mylonas I., Friese K. and Jeschke U. (2009). Evaluation of a novel anti-mucin 1 (MUC1) antibody (PankoMab) as a potential diagnostic tool in human ductal breast cancer; comparison with two established antibodies. Onkologie 32, 238-244.
7. Doalto L., Paridaens R., Dodion P., Manil L., Rigo P. and Fruhling J. (1991). Value of CEA levels and of immunoscintigraphy (using CEAmarked antibodies) for the diagnosis and therapeutic monitoring of breast cancer: apropos of a case. Acta Clin. Belg. 46, 42-47. (InBelgium)
8. Fan X.N., Karsten U., Goletz S and Cao Y. (2010). Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol. Res. Pract. 206, 585-589.
9. Hempel P., Muller P., Oruzio D., Behr W., Brockmeyer C., Wochner M., Ehnle S., Riethmuller R. and Schlimok G. (2000). Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells. Cytotherapy 2, 287-295.
10. Karsten U., Diotel C., Klich G., Paulsen H., Goletz S., Muller S. and Hanisch F.G. (1998). Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res. 58, 2541-2549.
11. Karsten U., Serttas N., Paulsen H., Danielczyk A. and Goletz S. (2004). Binding patterns of DTR-specific antibodies reveal a glycosylationconditioned tumor-specific epitope of the epithelial mucin (MUC1). Glycobiology 14, 681-692.
12. Karsten U., von Mensdorff-Pouilly S. and Goletz S. (2005). What makes MUC1 a tumor antigen? Tumor Biol. 26, 217-220.
13. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., Hicklin D. and Kerbel R.S. (2002). Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8, 221-232.
14. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X. and Stern H.M. (2008). A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887.
15. Matsumura N., Yamamoto M., Aruga A., Takasaki K. and Nakano M. (2002). Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 94, 1770-1776.
16. Remmele W. and Stegner H.E. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8, 138-140.
17. Repp R., van Ojik H.H., Valerius T., Groenewegen G., Wieland G., Oetzel C., Stockmeyer B., Becker W., Eisenhut M., Steininger H., Deo Y.M., Blijham G.H., Kalden J.R., van de Winkel J.G. and Gramatzki M. (2003). Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br. J. Cancer. 89, 2234-2243.
18. Scholz C., Toth B., Barthell E., Mylonas I., Weissenbacher T., Friese K. and Jeschke U. (2009). Immunohistochemical expression of glycodelin in breast cancer correlates with estrogen-receptor alpha and progesterone-receptor A positivity. Histol. Histopathol. 24, 467-471.
19. Song E.Y., Qu C.F., Rizvi S.M., Raja C., Beretov J., Morgenstern A., Apostolidis C., Bruchertseifer F., Perkins A. and Allen B.J. (2008). Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model. Cancer Biol. Ther. 7, 76-80.
20. Stipsanelli E. and Valsamaki P. (2005). Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach. Hell. J. Nucl. Med. 8, 103-108.
21. Verheijen R.H., Massuger L.F., Benigno B.B., Epenetos A.A., Lopes A., Soper J.T., Markowska J., Vyzula R., Jobling T., Stamp G., Spiegel G., Thurston D., Falke T., Lambert J. and Seiden M.V. (2006). Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol. 24, 571-578.
22. Xia W., Gerard C.M., Liu L., Baudson N.M., Ory T.L. and Spector N.L. (2005). Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24, 6213-6221.
23. Zotter S., Lossnitzer A., Hageman P.C., Delemarre J.F., Hilkens J. and Hilgers J. (1987). Immunohistochemical localization of the epithelial marker MAM-6 in invasive malignancies and highly dysplastic adenomas of the large intestine. Lab. Invest. 57, 193-199.